Loading patent…
AssigneesBristol-Myers Squibb Company, Roche Innovation Center Copenhagen A/S
InventorsRichard E. Olson, Angela M. Cacace, Jere E. Meredith, Jr., Nino Devidze, James K. Loy, Carl J. Baldick, Annapurna Pendri, Ivar M. McDonald, Peter Hagedorn, Marianne Lerbech Jensen
Estimating the term…
The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.
A method of preparing an antisense oligonucleotide (ASO) that is capable of specifically binding to a target region of a SNCA transcript, the method comprising synthesizing the contiguous nucleotide sequence of AtTcctttacaccACAC (SEQ ID NO:
Dependencies are inferred from the claim text.